TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00187083
Drug: E. coli Asparaginase, PEG-L-asparaginase
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description section for details of treatment interventions.
Study: NCT00892437
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
Study: NCT00892437
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Study: NCT00892437
Drug: COBI placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match COBI administered orally once daily
Study: NCT00892437
Drug: RTV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match RTV administered orally once daily
Study: NCT04017403
Drug: Bifidobacterium triple live capsule
Normalized name: Bifidobacterium infantis Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium triple live capsules, indications for acute and chronic diarrhea and constipation caused by intestinal flora imbalance, can also be used for the treatment of mild to moderate acute diarrhea, chronic diarrhea and indigestion, bloating, and adjuvant treatment of intestinal flora Endotoxemia caused by disorders.
Study: NCT04017403
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos were administrated as same as the bifidobacterium live capsule
Study: NCT03185130
Drug: Normal Saline 20mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
Study: NCT03431610
Drug: SB414 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03431610
Drug: SB414 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03431610
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT01591980
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsules will be administered in the same way.
Study: NCT02750410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00327392
Drug: AQUAVAN® (fospropofol disodium) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01894516
Drug: GLPG0634
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG0634 capsules.
Study: NCT01894516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules.
Study: NCT00278525
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard of care medication will be given
Study: NCT02886715
Drug: Tazorac®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.
Study: NCT02886715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.
Study: NCT00356915
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
Study: NCT03932240
Drug: Cryoprecipitate
Normalized name: Cryoprecipitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard transfusion algorithm includes two units of cryoprecipitate, which result in a median post-operative fibrinogen level of 286mg/dL.
Study: NCT00294125
Drug: Flavocoxid
Normalized name: Flavocoxid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily flavocoxid for 12 weeks
Study: NCT00294125
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo for 12 weeks
Study: NCT01152853
Drug: PF00299804
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
Study: NCT02371629
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
Study: NCT02371629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to NVA237
Study: NCT01330290
Drug: Neupro®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
Study: NCT00824421
Drug: UK-453, 061
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
Study: NCT02298101
Drug: Technetium-99m - Diethylenetriaminepentaacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution placed on the nebulizer reservoir
Study: NCT02201940
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg FDC tablet administered orally once daily
Study: NCT02201940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT04391764
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
Study: NCT03982225
Drug: Polyene phosphatidylcholine injection
Normalized name: phosphatidylcholine, soybean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated as an injectable solution containing Polyene Phosphatidylcholine at two concentration of 25 mg/mL and 50 mg/mL.
Study: NCT03982225
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate buffered saline placebo for injection
Study: NCT02354950
Drug: GSK1265744 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
Study: NCT03844438
Drug: LPM3480226
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose was 50 mg and the subsequent dose was increased according to the protocol of 100 mg, 200 mg, 400 mg, 600mg.
Study: NCT02242396
Drug: Telmisartan hydrochlorothiazide
Normalized name: hydrochlorothiazide / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00954785
Drug: Diclofenac 50 mg tds
Normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
Study: NCT00954785
Drug: Etoricoxib 120 mg mane
Normalized name: etoricoxib 120 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
Study: NCT01965925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
Study: NCT00004867
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02009618
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04193202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered twice daily as a placebo oral tablet matching gefapixant
Study: NCT01602315
Drug: BYL719 as film-coated (FC) whole tablets
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral alpha-specific PI3K inhibitor
Study: NCT01602315
Drug: BYL719 drink suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral alpha-specific PI3K inhibitor
Study: NCT01984398
Drug: 12.5 mg Androxal Formulation A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 12.5 mg Androxal formulation A
Study: NCT01984398
Drug: 12.5 mg Androxal Formulation B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 12.5 mg Androxal Formulation B
Study: NCT01984398
Drug: 25 mg Androxal Formulation A
Normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 25 mg Androxal formulation A
Study: NCT01984398
Drug: 25 mg Androxal Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 25 mg Androxal formulation B
Study: NCT00800007
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
Study: NCT03846843
Drug: OCR-002 IR Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCR-002 3 gram immediate release (IR) tablet for oral administration
Study: NCT03846843
Drug: OCR-002 Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCR-002 5 gram solution for oral administration
Study: NCT03846843
Drug: OCR-002 IV Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: OCR-002 5 gram solution for intravenous (IV ) administration
Study: NCT00803894
Drug: MK0752
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
Study: NCT00803894
Drug: Comparator: MK0752.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
Study: NCT00803894
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose placebo capsules: there will be a 7-day washout period between treatments.
Study: NCT04485403
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 800 mg/day ( 2 x 400mg) for 3 weeks in women with a bodyweight \<70 kg, and a dose of 1200 mg/day (3x400mg) in women weighing\> 70kg. The effects of treatment will be compared on the basis of changes in the hormonal profile and inflammatory markers, as well as the clinical assessment of the patient.
Study: NCT03197493
Drug: carbidopa-levodopa 25-100 mg
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
Study: NCT01834820
Drug: Epinephrine and Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01834820
Drug: Hypertonic Saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01834820
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00373789
Drug: Botulinum Toxin A, bladder detrusor muscle injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
Study: NCT00373789
Drug: Vehicle saline as placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
Study: NCT00856401
Drug: PTH1-84 in parent study
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
Study: NCT00942682
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once daily in the morning
Study: NCT00335244
Drug: Placebo of intravenous L-citrulline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo of intravenous L-citrulline
Study: NCT03524391
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual Care group had standard chemotherapy regimens
Study: NCT02496884
Drug: DS-5565
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-5565 7.5 mg tablet for oral use
Study: NCT02496884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet for oral use to match DS-5565 7.5 mg tablet
Study: NCT02019719
Drug: GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
Study: NCT02019719
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film coated tablets of GSK1278863 matching placebo for oral administration.
Study: NCT02076373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. administration
Study: NCT02031276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for risankizumab administered by IV infusion
Study: NCT01148810
Drug: BAF312
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01148810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01136239
Drug: N-acetycysteine (600mg twice daily)
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetycysteine (600mg twice daily) for one year
Study: NCT01136239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (600mg twice daily)
Study: NCT01523821
Drug: Alpha 1-Proteinase Inhibitor, Human 1 MG [Glassia]
Normalized name: alpha 1-proteinase inhibitor, human 1 MG [Glassia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha 1-Proteinase Inhibitor, Human 1 MG \[Glassia\] at various levels over different days
Study: NCT01586442
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
Study: NCT01586442
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
Study: NCT06195228
Drug: Other Targets: precise treatment based on the target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advanced thyroid cancer patients who had other treatment targets not included above
Study: NCT00246259
Drug: Oral Antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
Study: NCT04342065
Drug: Celecoxib capsules
Normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: received celecoxib 200 mg 2 hours preoperative and the same dose 6 hours postoperative.
Study: NCT00814931
Drug: CXB722
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg CXB722 oral liquid suspension twice a day for 8 days
Study: NCT00814931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching oral liquid suspension placebo twice a day for 8 days
Study: NCT01397019
Drug: Oxaliplatin, irinotecan, 5-FU & leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
Study: NCT05072405
Drug: Simvastatin 20 mg (Zocor®, MSD)
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.
Study: NCT05072405
Drug: rosuvastatin 10 mg (Crestor®, Astra Zeneca)
Normalized name: rosuvastatin calcium 10 MG [Crestor]
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
Study: NCT00385021
Drug: 5-Fluorouracil, leucovorin, oxaliplatin, avastin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01552343
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
Study: NCT04976465
Drug: Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug:~1. Prednisone 5-30mg, po, once per day(Qd) prescribed if needed and adjusted due to patient response Other Names: Pred~2. Hydroxychloroquine 100-200mg, po, twice per day (Bid) prescribed if needed and adjusted due to patient response.~   Other Names: HCQ~3. Aspirin 100mg, po, once per day (Qd) prescribed if needed and adjusted due to patient response to 32 weeks of pregnancy. 75mg po, once per day (Qd) to 34 weeks of pregnancy. 50mg po, once per day (Qd) to 36 weeks of pregnancy.~   Other Names: Asp~4. Low molecular weight heparin Enoxaparin 40-60mg, ih, Subcutaneous injection, once per day (Qd) or twice per day (Bid) if needed and adjusted due to patient response.~Other Names: LMWH
Study: NCT00070447
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070447
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02981290
Drug: Renodapt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
Study: NCT02981290
Drug: Mycept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study: NCT02981290
Drug: Cellmune
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study: NCT01009294
Drug: Chronic Corticosteroid Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrollment was stratified to ensure evaluation of approximately half of the participants were receiving chronic corticosteroid therapy and approximately half of participants were not receiving chronic corticosteroid therapy. Therefore, 3 out of 6 participants were receiving chronic corticosteriod therapy. For the participants receiving chronic corticosteriod therapy, a stable corticosteriod regimen was to be maintained during the study.
Study: NCT03247400
Drug: 1% simvastatin-acid sodium salt ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% simvastatin-acid sodium salt ointment applied onto a predefined limb
Study: NCT03247400
Drug: 1% atorvastatin calcium salt ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% atorvastatin calcium salt ointment applied onto a predefined limb
Study: NCT00393822
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one bolus IV injection at 120 μg/kg/day of matched placebo
Study: NCT01824602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sugar pills
Study: NCT05042245
Drug: Ornithine aspartate granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine aspartate granules in the experimental arm.
Study: NCT05042245
Drug: Silymarin capsule
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin capsules in the active comparator arm.
Study: NCT05042245
Drug: Silymarin capsule simulant
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin capsule simulant in the experimental arm.
Study: NCT05042245
Drug: Ornithine aspartate granule simulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine aspartate granule simulant in the active comparator arm.
Study: NCT03008512
Drug: Genexol-PM
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02677584
Drug: Prophylactic caffeine citrate
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
Study: NCT02677584
Drug: Therapeutic caffeine citrate
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
Study: NCT01615510
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, single administration
Study: NCT02603575
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
Study: NCT00839111
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
Study: NCT03019549
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT01912534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Study: NCT02128490
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen tablets
Study: NCT01434225
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
Study: NCT03969017
Drug: Nucleoside （acid）analogue (NAs)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both of NAs Group and NAs+Peg IFN Group will be treated with NAs as before enrollment.
Study: NCT02348307
Drug: FYU-981, (Oral single dosing)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the FYU-981 arm receive active drug, FYU-981.